The Non-Small Cell Lung Cancer (NSCLC) Pipeline report embraces in-depth commercial and clinical assessment of the Non-Small Cell Lung Cancer (NSCLC) pipeline products from the pre-clinical developmental phase to the marketed phase.
The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small Cell Lung Cancer (NSCLC) collaborations, mergers, acquisition, funding, designations, and other product-related details.
Get FREE sample copy at https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight
Non-Small Cell Lung Cancer (NSCLC) Therapies Covered in the report include:
AMG 510
SAR408701
PADCEV
TAK-788
Avelumab
Veliparib
Romiplostim
Canakinumab
Braftovi+Mektovi
Sitravatinib (MGCD516)
INCMGA00012/MGA012
TEPMETKO (tepotinib)
And many more.
Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC) with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Non-Small Cell Lung Cancer (NSCLC) Treatment.
-
Non-Small Cell Lung Cancer (NSCLC) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Non-Small Cell Lung Cancer (NSCLC) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer (NSCLC) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The dynamics of the Non-small cell lung cancer (NSCLC) market is anticipated to change in the coming years owing to the improvement in the rise in healthcare spending across the world.
Non-Small Cell Lung Cancer (NSCLC) Companies:
Sanofi
AbbVie
Roche
Merk
Novartis
Pfizer
AstraZeneca
GlaxoSmithKline
Bristol-Myers-Squibb
Takeda Pharmaceuticals
Johnson & Johnson
And many others.
Report Highlights
-
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Non-Small Cell Lung Cancer (NSCLC).
-
In the coming years, the Non-Small Cell Lung Cancer (NSCLC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
-
The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small Cell Lung Cancer (NSCLC) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
-
A detailed portfolio of major pharma players who are involved in fueling the Non-Small Cell Lung Cancer (NSCLC) treatment market. Several potential therapies for Non-Small Cell Lung Cancer (NSCLC) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Small Cell Lung Cancer (NSCLC) market size in the coming years.
-
Our in-depth analysis of the Non-Small Cell Lung Cancer (NSCLC) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Non-Small Cell Lung Cancer (NSCLC)
3. Non-Small Cell Lung Cancer (NSCLC) Current Treatment Patterns
4. Non-Small Cell Lung Cancer (NSCLC) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-Small Cell Lung Cancer (NSCLC) Late Stage Products (Phase-III)
7. Non-Small Cell Lung Cancer (NSCLC) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Small Cell Lung Cancer (NSCLC) Discontinued Products
13. Non-Small Cell Lung Cancer (NSCLC) Product Profiles
14. Non-Small Cell Lung Cancer (NSCLC) Key Companies
15. Non-Small Cell Lung Cancer (NSCLC) Key Products
16. Dormant and Discontinued Products
17. Non-Small Cell Lung Cancer (NSCLC) Unmet Needs
18. Non-Small Cell Lung Cancer (NSCLC) Future Perspectives
19. Non-Small Cell Lung Cancer (NSCLC) Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Latest Reports By DelveInsight
Non-Small Cell Lung Cancer (NSCLC) Market Insight
DelveInsight’s “Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as Non-Small Cell Lung Cancer (NSCLC) market size, share, and trend analysis for the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
Peripheral Vascular Devices Market
DelveInsight’s ‘Peripheral Vascular Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Peripheral Vascular Devices Market and the historical and forecasted Peripheral Vascular Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/